Identification and validation of SERCA as a drug target for treating Notch1-related cancer. Inhibition of SERCA preferentially impairs maturation and activity of the mutant Notch1 receptor and induces G0/G1 arrest in NOTCH1 mutant cells. Here, NOTCH1 is linked to cancer.